While good glycemic control has been shown to prevent microvascular complications (e.g. retinopathy, nephropathy, neuropathy), only a few anti-diabetic agents have been shown to reduce macrovascular complications (e.g. cardiovascular events. Empagliflozin, a sodium glucose transporter-2 (SGLT2) inhibitor, not only reduced the risk of CV events but also all-cause mortality in the EMPA-REG OUTCOME study. Based on this data, the SGLT2 inhibitors were given favorable second-line treatment status in the most recent AACE/ACE clinical practice guidelines. But do all SGLT2 inhibitors confer the same benefits… and risks? The Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS) trial assessed the cardiovascular and renal benefits from long-term canagliflozin use. The results are both reassuring and unexpected.
Guest Author: Sean Lasota, Pharm.D.
Music by Good Talk
Making the GRADE: Durability of Glycemic Response in Type 2 Diabetes
Pop Health and Am Care Pharmacy Practice: Achieving Higher Quality, Lower Cost
Top Ten Things Every Clinician Should Know About the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Is In-Personal Care Better than Care Delivered at a Distance?
How Many Patients Can a Pharmacist Reasonably Manage? Estimating An Appropriate Panel Size
Is There a CLEAR Role for Bempedoic Acid in Cardiovascular Risk Reduction?
Is MBSR* as Good as Meds for Anxiety Disorders?
GLP-1 Receptor Agonists and SGLT2 Inhibitors: Don’t Sugarcoat the Costs!
Is Combination Therapy Superior to Monotherapy for Painful Diabetic Peripheral Neuropathy?
How VITAL is Vitamin D in Preventing Statin Associated Muscle Symptoms (SAMS)?
Under Pressure: Measuring and Managing Hypertension
Top Ten Things Every Clinician Should Know About Payment for Pharmacists’ Patient Care Services
Complex Patient Case 2 - Managing Adverse Effects
Preventing Autoimmune Disease: Can Supplements Get the Job Done?
Top Ten Things Every Clinician Should Know About Treating Obesity
Managing RAAS-Inhibitor-Associated Hyperkalemia in Patients with CKD – A Balancing Act
Complex Patient Case - Women’s Health + Contraception
Top Ten Podcasts Every Ambulatory Care Clinician Should Know About
The Generic Levothyroxine Conundrum
Is Icosapent Ethyl a QALY-ty Investment?
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive